186 related articles for article (PubMed ID: 25665485)
1. The effects of estrogen on serum level and hepatocyte expression of PCSK9.
Guo W; Fu J; Chen X; Gao B; Fu Z; Fan H; Cui Q; Zhu X; Zhao Y; Yang T; Fan D; Zhou H
Metabolism; 2015 Apr; 64(4):554-60. PubMed ID: 25665485
[TBL] [Abstract][Full Text] [Related]
2. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells.
Starr AE; Lemieux V; Noad J; Moore JI; Dewpura T; Raymond A; Chrétien M; Figeys D; Mayne J
FEBS J; 2015 Jul; 282(14):2682-96. PubMed ID: 25913303
[TBL] [Abstract][Full Text] [Related]
3. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol.
Ghosh M; Gälman C; Rudling M; Angelin B
J Lipid Res; 2015 Feb; 56(2):463-9. PubMed ID: 25535288
[TBL] [Abstract][Full Text] [Related]
4. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
[TBL] [Abstract][Full Text] [Related]
5. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
Simonen P; Stenman UH; Gylling H
Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
[TBL] [Abstract][Full Text] [Related]
6. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
Jin K; Park BS; Kim YW; Vaziri ND
Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
[TBL] [Abstract][Full Text] [Related]
7. Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.
Tavori H; Fan D; Blakemore JL; Yancey PG; Ding L; Linton MF; Fazio S
Circulation; 2013 Jun; 127(24):2403-13. PubMed ID: 23690465
[TBL] [Abstract][Full Text] [Related]
8. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
[TBL] [Abstract][Full Text] [Related]
9. Relationship between testosterone, estradiol and circulating PCSK9: Cross-sectional and interventional studies in humans.
Ooi TC; Raymond A; Cousins M; Favreau C; Taljaard M; Gavin C; Jolly EE; Malone S; Eapen L; Chretien M; Mbikay M; Mayne J
Clin Chim Acta; 2015 Jun; 446():97-104. PubMed ID: 25858546
[TBL] [Abstract][Full Text] [Related]
10. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
[TBL] [Abstract][Full Text] [Related]
11. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
[TBL] [Abstract][Full Text] [Related]
12. Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.
Brouwers MC; Konrad RJ; van Himbergen TM; Isaacs A; Otokozawa S; Troutt JS; Schaefer EJ; van Greevenbroek MM; Stalenhoef AF; de Graaf J
Nutr Metab Cardiovasc Dis; 2013 Nov; 23(11):1115-21. PubMed ID: 23333725
[TBL] [Abstract][Full Text] [Related]
13. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
Urban D; Pöss J; Böhm M; Laufs U
J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
[TBL] [Abstract][Full Text] [Related]
14. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
[TBL] [Abstract][Full Text] [Related]
15. The effect of insulin on circulating PCSK9 in postmenopausal obese women.
Awan Z; Dubuc G; Faraj M; Dufour R; Seidah NG; Davignon J; Rabasa-Lhoret R; Baass A
Clin Biochem; 2014 Aug; 47(12):1033-9. PubMed ID: 24721682
[TBL] [Abstract][Full Text] [Related]
16. A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.
Gauthier MS; Pérusse JR; Awan Z; Bouchard A; Tessier S; Champagne J; Krastins B; Byram G; Chabot K; Garneau P; Rabasa-Lhoret R; Faubert D; Lopez MF; Seidah NG; Coulombe B
Methods; 2015 Jun; 81():66-73. PubMed ID: 25770357
[TBL] [Abstract][Full Text] [Related]
17. Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.
Nekaies Y; Baudin B; Kelbousi S; Sakly M; Attia N
J Diabetes Complications; 2015; 29(8):1165-70. PubMed ID: 26412029
[TBL] [Abstract][Full Text] [Related]
18. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other.
Butkinaree C; Canuel M; Essalmani R; Poirier S; Benjannet S; Asselin MC; Roubtsova A; Hamelin J; Marcinkiewicz J; Chamberland A; Guillemot J; Mayer G; Sisodia SS; Jacob Y; Prat A; Seidah NG
J Biol Chem; 2015 Jul; 290(30):18609-20. PubMed ID: 26085104
[TBL] [Abstract][Full Text] [Related]
19. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9.
Hori M; Ishihara M; Yuasa Y; Makino H; Yanagi K; Tamanaha T; Kishimoto I; Kujiraoka T; Hattori H; Harada-Shiba M
J Clin Endocrinol Metab; 2015 Jan; 100(1):E41-9. PubMed ID: 25313916
[TBL] [Abstract][Full Text] [Related]
20. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population.
Cui Q; Ju X; Yang T; Zhang M; Tang W; Chen Q; Hu Y; Haas JV; Troutt JS; Pickard RT; Darling R; Konrad RJ; Zhou H; Cao G
Atherosclerosis; 2010 Dec; 213(2):632-6. PubMed ID: 21040917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]